Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of Urology.
نویسندگان
چکیده
On December 10, 2012, the FDA approved the use of abiraterone acetate in patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC) prior to the use of chemotherapy (CT). The EMA, after a positive preliminary comment, approved on December 21, 2012, the use of abiraterone in the same case. This molecule has approved indication in CRPC, both post-CT and pre-CT, the latter being where the urologist has a very important role in its prescription. This compound blocks the complex 17 of the p450 cytochrome, inhibiting androgen production at all levels: testis, adrenal gland, and even intracrine production by prostate tumor cells themselves.1 The clinical benefits of abiraterone along with prednisone (PDN) have been studied in a phase III, multinational, multicenter, randomized, double-blind, placebo-controlled trial in patients with metastatic CRPC and asymptomatic or mildly symptomatic chemo-naïve ones.2 1088 patients were randomized 1:1, having as primary objectives progression-free recurrence (rPFS) and overall survival (OS). The secondary objectives were time to opiate use, time to onset of chemotherapy, and time to deterioration of the ECOG-PS. In a first interim analysis, we could demonstrate a significant impact of the use of abiraterone + PDN in rPFS, and a significant trend, although not significant, to improve OS. Likewise, it was possible to demonstrate an improvement in pain scores,
منابع مشابه
A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملA Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملAssessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening
Background: Prostate cancer is the second form of cancer among men worldwide. For early cancer detection, we should identify tumors in initial stages before the physical signs become visible. The present study aims to evaluate the diagnostic value of cell-free DNA (cfDNA), its comparison with prostate-specific antigen (PSA) level in prostate cancer screening and also in patients with localized ...
متن کاملAssociation between prostate specific antigen change over time and prostate cancer recurrence risk: a joint model
Background: Prostate specific antigen (PSA) is an important biomarker to monitor patients after treated with radiation therapy (RT). The aim of this study is to evaluate the relationship between the PSA data and prostate cancer recurrence using the joint modeling. Methods: This historical cohort study was performed on 422 prostate cancer patients. Inclusion criteria included: patients with loc...
متن کاملبررسی نقش ژن CYP1B1 در سرطان پروستات در دو جمعیت ایرانی و هندی
Prostate cancer (PCa) is the most common non-skin cancer and the second leading cause of cancer death among men in the world. Growth, maintenance and the expression of genes involved in the production of steroids, may alter the susceptibility of prostate cancer. One such gene, CYP1B1 (cytochrome P450, family 1, subfamily B, polypeptide 1) is involved in the activation of many carcinogens and i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Actas urologicas espanolas
دوره 37 6 شماره
صفحات -
تاریخ انتشار 2013